Global Point of Care
Global Point of Care
The Society of Critical Care Medicine reports that sepsis affects approximately 1.7 million patients each year, resulting in over 270,000 deaths1. Sepsis carries a greater mortality than Breast Cancer and AIDS combined2, costing over $24 billion dollars annually3. Early identification and treatment has been shown to reduce mortality by nearly 50% with the completion of the Sepsis Care bundles4. Over 85% of sepsis patients arrive to the hospital with Sepsis5, so an evidence-based process for early detection and treatment is key to reducing complications and mortality.
The Surviving Sepsis Guidelines are a systematic, standardized evidence-based approach to the early recognition and treatment of the sepsis patient. Average length of stay (LOS) for the septic shock patient is 16.5 days with a cost of approximately $19,000 per case6. Sepsis accounts for 13% of total U.S. hospital costs7, with early recognition in both the ED and ICU the average LOS can be reduced8. The use of the Sepsis Care bundles results in better patient outcomes, shorter length of stay, and an overall reduction in sepsis mortality9.
Understanding the evolution of the Sepsis Care bundles and how each member of the healthcare team can contribute to the recognition and treatment of sepsis is vital to the patient care process. A key component of treatment is utilizing the SIRS (Systemic Inflammatory Response Syndrome) criteria early in the ED and using the qSOFA (Quick Sequential Organ Failure Assessment) after admission to help facilitate early sepsis recognition.
One P.A.C.E.® contact hour will be provided for this basic level session. Abbott is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. • This session is approved for one Florida CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563 • This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.00 CERPs, Synergy CERP Category A, File Number 24306. Approval refers to recognition of continuing education only and does not imply AACN approval or endorsement of the content of this educational activity, or the products mentioned.
1. Centers for Disease Control and Prevention. 2021. Sepsis Clinical Information. [online] Available at: [Accessed 1 June 2021].
2. UCLA Health. 2021. The World Sepsis Day Fact Sheet. [online] Available at: [Accessed 1 June 2021].
3. Paoli, C., 2021. Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level. [online] NCBI. Available at: [Accessed 1 June 2021].
4. Vincent, J., 2021. Reducing mortality in sepsis: new directions. [online] NCBI. Available at: [Accessed 1 June 2021].
5. 2021. Sepsis Fact Sheet. [ebook] Available at: [Accessed 1 June 2021].
6. Paoli, C., 2021. Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level. [online] NCBI. Available at: [Accessed 1 June 2021].
7. Padkin, A., 2021. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. [online] Society of Critical Care Medicine. Available at: [Accessed 1 June 2021].
8. Hackethal, V., 2018. Fewer Deaths After Sepsis Protocol Mandate. [online] Medscape. Available at: [Accessed 1 June 2021].
9. Hackethal, V., 2018. Fewer Deaths After Sepsis Protocol Mandate. [online] Medscape. Available at: [Accessed 1 June 2021]
Lori Muhr, DNP, MHSM/MHA, APRN-Rx, ACNS-BC, CCRN, CEN, LSS-BBC
Clinical Nurse Specialist
A Leader In Rapid Point-of-care Diagnostics.
©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.